These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35585374)

  • 1. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
    Benatar M; Wuu J; Andersen PM; Bucelli RC; Andrews JA; Otto M; Farahany NA; Harrington EA; Chen W; Mitchell AA; Ferguson T; Chew S; Gedney L; Oakley S; Heo J; Chary S; Fanning L; Graham D; Sun P; Liu Y; Wong J; Fradette S
    Neurotherapeutics; 2022 Jul; 19(4):1248-1258. PubMed ID: 35585374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.
    Oliveira Santos M; de Carvalho M
    Expert Rev Neurother; 2024 Jun; 24(6):549-553. PubMed ID: 38758193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice.
    Meyer T; Schumann P; Weydt P; Petri S; Koc Y; Spittel S; Bernsen S; Günther R; Weishaupt JH; Dreger M; Kolzarek F; Kettemann D; Norden J; Boentert M; Vidovic M; Meisel C; Münch C; Maier A; Körtvélyessy P
    Muscle Nerve; 2023 Jun; 67(6):515-521. PubMed ID: 36928619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial of Antisense Oligonucleotide Tofersen for
    Miller TM; Cudkowicz ME; Genge A; Shaw PJ; Sobue G; Bucelli RC; Chiò A; Van Damme P; Ludolph AC; Glass JD; Andrews JA; Babu S; Benatar M; McDermott CJ; Cochrane T; Chary S; Chew S; Zhu H; Wu F; Nestorov I; Graham D; Sun P; McNeill M; Fanning L; Ferguson TA; Fradette S;
    N Engl J Med; 2022 Sep; 387(12):1099-1110. PubMed ID: 36129998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion.
    Benatar M; Wuu J; Andersen PM; Lombardi V; Malaspina A
    Ann Neurol; 2018 Jul; 84(1):130-139. PubMed ID: 30014505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for
    Miller T; Cudkowicz M; Shaw PJ; Andersen PM; Atassi N; Bucelli RC; Genge A; Glass J; Ladha S; Ludolph AL; Maragakis NJ; McDermott CJ; Pestronk A; Ravits J; Salachas F; Trudell R; Van Damme P; Zinman L; Bennett CF; Lane R; Sandrock A; Runz H; Graham D; Houshyar H; McCampbell A; Nestorov I; Chang I; McNeill M; Fanning L; Fradette S; Ferguson TA
    N Engl J Med; 2020 Jul; 383(2):109-119. PubMed ID: 32640130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and patient-reported outcomes and neurofilament response during tofersen treatment in SOD1-related ALS-A multicenter observational study over 18 months.
    Meyer T; Schumann P; Weydt P; Petri S; Weishaupt JH; Weyen U; Koch JC; Günther R; Regensburger M; Boentert M; Wiesenfarth M; Koc Y; Kolzarek F; Kettemann D; Norden J; Bernsen S; Elmas Z; Conrad J; Valkadinov I; Vidovic M; Dorst J; Ludolph AC; Hesebeck-Brinckmann J; Spittel S; Münch C; Maier A; Körtvélyessy P
    Muscle Nerve; 2024 Sep; 70(3):333-345. PubMed ID: 39031772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofersen: First Approval.
    Blair HA
    Drugs; 2023 Jul; 83(11):1039-1043. PubMed ID: 37316681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entity.
    Benatar M; Granit V; Andersen PM; Grignon AL; McHutchison C; Cosentino S; Malaspina A; Wuu J
    Brain; 2022 Oct; 145(10):3500-3508. PubMed ID: 35594156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [SOD1 gene therapy delays ALS disease progression].
    Forsberg K; Karlsborg M; Salvesen L; Svenstrup K; Winroth I; Berntsson H; M Andersen P
    Lakartidningen; 2024 Apr; 121():. PubMed ID: 38666665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic alterations precede neurofilament changes in presymptomatic ALS gene carriers.
    Dorst J; Weydt P; Brenner D; Witzel S; Kandler K; Huss A; Herrmann C; Wiesenfarth M; Knehr A; Günther K; Müller K; Weishaupt JH; Prudlo J; Forsberg K; Andersen PM; Rosenbohm A; Schuster J; Roselli F; Dupuis L; Mayer B; Tumani H; Kassubek J; Ludolph AC
    EBioMedicine; 2023 Apr; 90():104521. PubMed ID: 36917918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment of SOD1 ALS with tofersen: a multicentre experience in 17 patients.
    Sabatelli M; Cerri F; Zuccarino R; Patanella AK; Bernardo D; Bisogni G; Tanel R; Sansone V; Filosto M; Lattante S; Martello F; Doronzio PN; Stano S; Zanfini BA; Coccia M; Costantini EM; Lizio A; Lucioli G; Padovani A; Merlini GP; Conte A
    J Neurol; 2024 Aug; 271(8):5177-5186. PubMed ID: 38829431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breaking barriers with tofersen: Enhancing therapeutic opportunities in amyotrophic lateral sclerosis.
    Saini A; Chawla PA
    Eur J Neurol; 2024 Feb; 31(2):e16140. PubMed ID: 37975798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofersen decreases neurofilament levels supporting the pathogenesis of the SOD1 p.D91A variant in amyotrophic lateral sclerosis patients.
    Weishaupt JH; Körtvélyessy P; Schumann P; Valkadinov I; Weyen U; Hesebeck-Brinckmann J; Weishaupt K; Endres M; Andersen PM; Regensburger M; Dreger M; Koch JC; Conrad J; Meyer T
    Commun Med (Lond); 2024 Jul; 4(1):150. PubMed ID: 39054363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of SOD1 variants in Chinese patients with familial amyotrophic lateral sclerosis.
    Li H; Yuan L; Yang H; Guo Y; Zheng W; Fan K; Deng S; Gong L; Xu H; Yang Z; Cheng J; Kang M; Deng H
    QJM; 2023 May; 116(5):365-374. PubMed ID: 36661322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelitis as a side effect of tofersen therapy in SOD1-associated ALS.
    Reilich P; Schöberl F; Hiebeler M; Tonon M; Ludolph AC; Senel M
    J Neurol; 2024 Apr; 271(4):2114-2118. PubMed ID: 38066205
    [No Abstract]   [Full Text] [Related]  

  • 17. Antisense Oligonucleotides for the Study and Treatment of ALS.
    Boros BD; Schoch KM; Kreple CJ; Miller TM
    Neurotherapeutics; 2022 Jul; 19(4):1145-1158. PubMed ID: 35653060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS).
    Abati E; Bresolin N; Comi G; Corti S
    Expert Opin Ther Targets; 2020 Apr; 24(4):295-310. PubMed ID: 32125907
    [No Abstract]   [Full Text] [Related]  

  • 19. Inclusions in macrophages of the cerebrospinal fluid during treatment with Tofersen.
    Sparasci D; Castelli C; Staedler C; Gobbi C; Ripellino P
    Muscle Nerve; 2023 Feb; 67(2):E3-E5. PubMed ID: 36477882
    [No Abstract]   [Full Text] [Related]  

  • 20. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex.
    Thomsen GM; Gowing G; Latter J; Chen M; Vit JP; Staggenborg K; Avalos P; Alkaslasi M; Ferraiuolo L; Likhite S; Kaspar BK; Svendsen CN
    J Neurosci; 2014 Nov; 34(47):15587-600. PubMed ID: 25411487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.